Annals of Surgical Oncology最新文献

{"title":"Isolated Limb Infusion or Perfusion as First-Line Versus Second-Line Therapy for In-Transit Metastatic Melanoma.","authors":"Michelle M Dugan, Aleena Boby, Helana Ghali, Shaliz Aflatooni, Danielle K DePalo, Anne Huibers, Wenyi Fan, Roger Olofsson Bagge, Jonathan S Zager","doi":"10.1245/s10434-025-17403-9","DOIUrl":"10.1245/s10434-025-17403-9","url":null,"abstract":"<p><strong>Background: </strong>In-transit metastases (ITM) develops in 10% of patients with high-risk melanoma. Isolated limb infusion and perfusion (ILI/ILP) are well-established therapies for ITM, but the ideal line of therapy has not been defined. This study compared ILI/ILP as first- versus second-line therapy.</p><p><strong>Methods: </strong>An international multi-institution retrospective study reviewed patients with unresectable ITM who underwent ILI/ILP from 2006 to 2023.</p><p><strong>Results: </strong>The study was comprised of 364 patients (55% female) with a median age of 71 years. Of the 364 patients, 329 (90%) were treated with ILI/ILP as first-line therapy, and 35 (10%) were treated with ILI/ILP as second-line therapy. The median follow-up period was 3 years. Lower-extremity disease was present in 85% (n = 310) of the patients. The best response for ILI/ILP as any line of therapy was 54% complete response (CR), 29 % partial response (PR), 8.2% stable disease (SD), and 9.1% progressive disease (PD). The CR/PR/SD/PD rates for first- versus second-line therapy were respectively 55%/ 29%/ 7.5%/ 8.2% versus 41%/ 26%/ 15%/ 18% (P = 0.09). As first-line therapy, ILI/ILP was associated with a significantly higher overall response rate (ORR) of 84% versus 68% (odds ratio [OR], 2.9; 95% confidence interval [CI], 1.2-6.9; P = 0.02). The comparison showed no statistical difference in median in-field progression-free survival (PFS) (10.8 vs. 8.1 months; P = 0.2), out-of-field PFS (13.5 vs. 15.3 months; P = 0.4), or overall survival (OS) (4.1 vs. 4.5 years; P = 0.7).</p><p><strong>Conclusion: </strong>For patients with unresectable melanoma ITM, ILI/ILP either as first- or second-line therapy provides high overall response rates. Although first-line therapy had a higher ORR, this did not translate to a difference in in-field PFS, indicating that ILI/ILP is indeed an effective salvage therapy also as second-line therapy.</p>","PeriodicalId":8229,"journal":{"name":"Annals of Surgical Oncology","volume":" ","pages":"5397-5401"},"PeriodicalIF":3.4,"publicationDate":"2025-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143954579","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"ASO Author Reflections: Carcinoembryonic Antigen as a Predictor of Failure to Reach Surgery in Patients with Borderline Resectable Pancreatic Cancer Undergoing Neoadjuvant Therapy.","authors":"Arielle Jacover, Niv Pencovich","doi":"10.1245/s10434-025-17536-x","DOIUrl":"10.1245/s10434-025-17536-x","url":null,"abstract":"<p><p>Borderline resectable pancreatic ductal adenocarcinoma (BR-PDAC) presents a therapeutic challenge, balancing the benefits of neoadjuvant therapy (NT) against the risk of missing the opportunity for cure by upfront surgery. In this retrospective study, we evaluated real-world outcomes in patients with BR-PDAC undergoing NT and identified elevated baseline carcinoembryonic antigen (CEA) as an independent predictor of failure to reach surgery, primarily due to local tumor progression. Our findings suggest that CEA may serve as a practical biomarker to guide treatment selection between NT and upfront surgery.</p>","PeriodicalId":8229,"journal":{"name":"Annals of Surgical Oncology","volume":" ","pages":"5426-5427"},"PeriodicalIF":3.4,"publicationDate":"2025-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12222394/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144172543","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"ASO Author Reflections: Intraoperative Radiation Therapy (IORT): Near Dead in the USA.","authors":"Melvin J Silverstein, Brian Kim, Kevin Lin, Shane Lloyd","doi":"10.1245/s10434-025-17611-3","DOIUrl":"10.1245/s10434-025-17611-3","url":null,"abstract":"","PeriodicalId":8229,"journal":{"name":"Annals of Surgical Oncology","volume":" ","pages":"5580-5582"},"PeriodicalIF":3.4,"publicationDate":"2025-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12222380/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144224110","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"ASO Author Reflections: Augmenting the Future Liver Remnant Prior to Major Hepatectomy: A Review of Options on the Menu.","authors":"Paul Wong, Laleh G Melstrom","doi":"10.1245/s10434-025-17679-x","DOIUrl":"10.1245/s10434-025-17679-x","url":null,"abstract":"","PeriodicalId":8229,"journal":{"name":"Annals of Surgical Oncology","volume":" ","pages":"5728-5729"},"PeriodicalIF":3.4,"publicationDate":"2025-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12222293/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144282263","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Prophylactic Lymphovenous Bypass for Breast Cancer-Related Lymphedema: Research Challenges, Statistical Pitfalls, and Solutions.","authors":"Georgios Karamitros, Michael P Grant, Gregory A Lamaris","doi":"10.1245/s10434-025-17200-4","DOIUrl":"10.1245/s10434-025-17200-4","url":null,"abstract":"","PeriodicalId":8229,"journal":{"name":"Annals of Surgical Oncology","volume":" ","pages":"5845-5846"},"PeriodicalIF":3.4,"publicationDate":"2025-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143656078","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Extended Left Hepatectomy with Inferior Vena Cava Replacement and Right Hepatic Vein Re-implantation Under In Situ Cooling and Venous Bypass for Advanced Intrahepatic Cholangiocarcinoma: H123458-RHV-IVC.","authors":"Edoardo Maria Muttillo, Mohammed Ghallab, Daniel Cherqui","doi":"10.1245/s10434-025-17278-w","DOIUrl":"10.1245/s10434-025-17278-w","url":null,"abstract":"<p><strong>Background: </strong>Resection of intrahepatic cholangiocarcinoma (iCCA) with invasion of major venous structures is controversial because of its significant morbidity and mortality and questionable oncological value.^1,2 We report on a case of long-term survival after extreme liver surgery in a patient with advanced iCCA.³ METHODS: A 51-year-old woman was referred for locally advanced, biopsy-proven iCCA. Imaging showed an 8 cm mass involving the inferior vena cava (IVC) and hepatic veins confluence with no evidence of extrahepatic disease. The procedure included an extended left hepatectomy with IVC and right hepatic vein (RHV) resection and reconstruction. The measured future liver remnant was 884 mL.</p><p><strong>Results: </strong>The procedure began with liver mobilization, hilar dissection, and lymphadectomy. Total vascular exclusion (TVE) was required and an elective venous bypass was created using the femoral and inferior mesenteric veins to the axillary vein. TVE was placed, and liver cooling was performed using 3 L of IGL solution delivered through the left portal vein stump, vented by an opening in the IVC. An extended left hepatectomy with en bloc resection of the retrohepatic IVC and main hepatic veins was performed. At the end of the transection, tumor contact was confirmed at the distal end of the RHV, resulting in an R1 vascular resection. A posterior patch of the RHV, including three constitutive branches, was kept for reconstruction. The IVC was replaced with a 16 Fr polytetrafluoroethylene (PTFE) graft, and an RHV patch was re-implanted on the side of the PTFE graft. The duration of both the surgery and the venous bypass was 560 and 130 min, respectively. The patient developed transient postoperative hepatic failure and was discharged on day 18. The pathology results indicated pT3N0 stage with a focal R1 margin, as seen during surgery. The patient declined adjuvant treatment. Eight years after surgery, the patient is alive and disease-free, with excellent quality of life.</p><p><strong>Conclusions: </strong>Extreme surgical approaches can allow for long-term survival and possible cure in selected patients with advanced iCCA. Focal R1 resection may occur in such instances and should be considered on a case-by-case decision.</p>","PeriodicalId":8229,"journal":{"name":"Annals of Surgical Oncology","volume":" ","pages":"5715-5716"},"PeriodicalIF":3.4,"publicationDate":"2025-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143957304","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Improving Urothelial Carcinoma Outcomes: The Powerful Combination of Neoadjuvant and Adjuvant Chemotherapy in the Perioperative Period.","authors":"Jincong Li, Yuxuan Song, Rui Chen, Hanlin Gao, Yang Liu, Yun Peng, Jilin Wu, Shicong Lai, Yiqing Du, Caipeng Qin, Tao Xu","doi":"10.1245/s10434-025-17154-7","DOIUrl":"10.1245/s10434-025-17154-7","url":null,"abstract":"<p><strong>Introduction: </strong>To enhance urothelial carcinoma (UC) prognosis, clinicians combine surgery with intraoperative (ICT), neoadjuvant (NACT), or adjuvant chemotherapy (ACT); however, studies on their individual and combined effects vary. Furthermore, studies on the combined use of ACT and NACT are scarce.</p><p><strong>Objective: </strong>This study aimed to assess the impact of these chemotherapy regimens on UC prognosis, particularly the effectiveness of ACT + NACT, using the Surveillance, Epidemiology, and End Results (SEER) database.</p><p><strong>Methods: </strong>We analyzed 45,211 UC cases from 2019 to 2021, focusing on renal, ureter, bladder, prostate, and urethra UC. Cox model-adjusted survival curves and multivariable Cox regression were performed using SPSS and R software.</p><p><strong>Results: </strong>Compared with ACT, NACT alone did not significantly impact survival (hazard ratio [HR] 0.834, 95% confidence interval [CI] 0.392-1.774, p = 0.638), whereas ACT + NACT (HR 0.389, 95% CI 0.169-0.895, p = 0.026) and ICT + ACT + NACT (HR 0.466, 95% CI 0.246-0.883, p = 0.019) positively affected UC prognosis. However, when compared with the combination of ACT + NACT, the combination of ICT + ACT + NACT did not show a statistically significant effect (HR 1.198, 95% CI 0.427-3.362, p = 0.731). Compared with no chemotherapy, ACT reduced renal UC survival (HR 1.430, 95% CI 1.105-1.850, p = 0.007) but improved ureter (HR 0.460, 95% CI 0.232-0.915, p = 0.027) and bladder UC survival (HR 0.605, 95% CI 0.466-0.785, p < 0.001).</p><p><strong>Conclusions: </strong>Prognosis after chemotherapy varied depending on different tumor locations. ACT reduced the prognosis of renal UC patients but elevated the prognosis of ureter UC and bladder UC patients. Distinct chemotherapy protocols have also yielded varying prognostic outcomes. For UC patients, the combination of ACT + NACT merits consideration in order to achieve better prognostic outcomes than the use of ACT or NACT alone. The adoption of ICT for UC patients may not be necessary.</p>","PeriodicalId":8229,"journal":{"name":"Annals of Surgical Oncology","volume":" ","pages":"6141-6150"},"PeriodicalIF":3.4,"publicationDate":"2025-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143727136","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"ASO Author Reflections: Anastomotic Leaks as a Surrogate of Biologic Vulnerability in Esophageal Squamous Cell Carcinoma Survival.","authors":"Chufeng Zeng, Xu Zhang, Bei Jia, Yi Hu, Peng Lin, Jianhua Fu, Hao Long, Tiehua Rong, Xiaodong Su","doi":"10.1245/s10434-025-17307-8","DOIUrl":"10.1245/s10434-025-17307-8","url":null,"abstract":"","PeriodicalId":8229,"journal":{"name":"Annals of Surgical Oncology","volume":" ","pages":"5972-5973"},"PeriodicalIF":3.4,"publicationDate":"2025-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143962735","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Mapping Knowledge Landscapes and Themes Trends of Breast Cancer Stem Cells: A Comprehensive Data-Mining-Based Study.","authors":"Kunming Cheng, Hui Di, Chunchun Wu, Hongjie Zhao, Wanqing Li","doi":"10.1245/s10434-025-17336-3","DOIUrl":"10.1245/s10434-025-17336-3","url":null,"abstract":"<p><strong>Background: </strong>Breast cancer, one of the most prevalent malignancies affecting women, poses significant treatment challenges due to the presence of breast cancer stem cells (BCSCs), which may contribute to treatment resistance, recurrence, and metastasis. Targeting BCSCs is increasingly seen as a promising therapeutic approach and a series of BCSC-related studies have been published recently. Nevertheless, no study has yet employed bibliometric analysis to examine the overall landscape of BCSC research.</p><p><strong>Materials and methods: </strong>All BCSC-related papers published between 1998 and 2023 were extracted from Web of Science Core Collection database. Bibliometric analysis was conducted by using VOSviewer, CiteSpace, and two online platforms.</p><p><strong>Results: </strong>A sum of 1771 papers including 1502 research articles and 269 review papers were ultimately included. The annual number of papers related to BCSCs has increased with the year, and the average annual growth rate during 1998 and 2023 was 18.4%. China and the USA undoubtedly dominate on a global scale, accounting for more than three-fifths of all publications. The University of Michigan System has published the most papers in this area. On the basis of the results from highly cited studies and high-frequency keywords, the research hotspots of BCSCs currently focus on domains including stemness and membrane biomarkers, key signaling pathways and molecules, therapeutic targeting and plasticity, therapeutic resistance, tumor characteristics, and microenvironment. In addition, the findings from keywords co-occurrence and burst analysis implied that research areas such as ferroptosis, GLI1, molecular docking, glycolysis, tumor microenvironment, copper, RUNX2, hyaluronic acid, cytokines, NANGO, long non-coding RNAs, triple-negative breast cancer, nanoparticles, Hippo pathway, and T cells warrant ongoing attention in the future. Additionally, TGFB1, STAT3, MYC, GAPDH, and INS were identified as the top five genes receiving the highest research focus within BCSC studies.</p><p><strong>Conclusions: </strong>This is the first study to comprehensively map the current state and global emerging trends in BCSC research through a bibliometric analysis. These findings provide a comprehensive overview of BCSC research and may serve as a useful reference for scholars and policymakers to identify emerging trends and prioritize future research directions in this field.</p>","PeriodicalId":8229,"journal":{"name":"Annals of Surgical Oncology","volume":" ","pages":"6031-6049"},"PeriodicalIF":3.4,"publicationDate":"2025-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143967581","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Predictive Factors for Chemotherapy Response in Colorectal Liver Metastasis: A Retrospective Study Utilizing Next-Generation Sequencing.","authors":"Li-Jun Wang, Quan Bao, Hong-Wei Wang, Long-Fei Huang, Jing-Qing Zhang, Ting-Ting Zhao, Ke-Min Jin, Xiao-Feng Liu, Kun Wang, Zhong-Wu Li, Bao-Cai Xing","doi":"10.1245/s10434-025-17320-x","DOIUrl":"10.1245/s10434-025-17320-x","url":null,"abstract":"<p><strong>Background: </strong>This study aimed to identify predictive factors for chemotherapy response in colorectal liver metastasis (CRLM) patients.</p><p><strong>Methods: </strong>Eligible participants with CRLM who had undergone at least two systemic chemotherapy cycles postdiagnosis were retrospectively analyzed. They were categorized as responders and nonresponders based on tumor size reduction. DNA extracted from tumor tissues was subjected to sequencing. Additionally, a comparative analysis of oncogenic pathways was conducted. Logistic regression analysis was conducted to determine predictive factors for chemotherapy response.</p><p><strong>Results: </strong>A total of 230 Chinese patients were analyzed. Significant differences in mutation distribution were found, particularly in the KRAS gene and several specific rare gene mutations (EP300, PTPRK, KMT2A, and ACVR1B), as well as in the PI3K and RTK-RAS pathways between the two groups. Gender, utilization of biological targeted agents (BTAs), KRAS gene mutations, PI3K pathway alterations, and specific rare gene mutations were used to construct a specific efficacy prediction model, achieving an area under the curve (AUC) of 0.73. Approximately 75% (87/116) of patients could potentially avoid BTAs based on the model's predictions. In a subgroup of 52 patients not using BTAs, simulation indicated that 10 patients could benefit by including BTAs, representing 32% (10 of 31) of initially nonresponsive patients.</p><p><strong>Conclusions: </strong>Gender, utilization of BTAs, and specific gene and pathway mutations may be significant predictors of chemotherapy response in CRLM patients. These findings highlight the role of genetic profiling in refining treatment strategies.</p>","PeriodicalId":8229,"journal":{"name":"Annals of Surgical Oncology","volume":" ","pages":"6067-6079"},"PeriodicalIF":3.4,"publicationDate":"2025-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143968182","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}